We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $472M
1-Year Est. Return 106.83%
This Fund
S&P 500
This Quarter Est. Return
+12.93%
1 Year Est. Return
+106.83%
3 Year Est. Return
+792.82%
5 Year Est. Return
+1,009.42%
10 Year Est. Return
AUM
$472M
AUM Growth
-$4.67M
Cap. Flow
-$33.3M
Cap. Flow %
-7.06%
Top 10 Hldgs %
98.96%
Holding
14
New
1
Increased
Reduced
1
Closed

Top Buys

Rank Stock Value
1
VTVT icon
vTv Therapeutics
VTVT
+$1.73M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$35M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$14.5B
$342M 72.48%
4,589,611
-500,000
-10% -$35M
GLUE icon
2
Monte Rosa Therapeutics
GLUE
$1.2B
$37.6M 7.98%
1,555,664
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.85B
$28.8M 6.1%
1,316,806
CMPS
4
Compass Pathways
CMPS
$1.82B
$20.3M 4.3%
1,432,336
BCAX
5
Bicara Therapeutics
BCAX
$1.53B
$16.9M 3.58%
568,919
BBOT
6
BridgeBio Oncology
BBOT
$712M
$7.76M 1.64%
1,018,018
SRRK icon
7
Scholar Rock
SRRK
$6.73B
$4.24M 0.9%
77,031
URGN icon
8
UroGen Pharma
URGN
$2.15B
$3.97M 0.84%
108,000
BMEA icon
9
Biomea Fusion
BMEA
$141M
$3.01M 0.64%
2,048,757
ACRS icon
10
Aclaris Therapeutics
ACRS
$882M
$2.3M 0.49%
434,455
EPRX
11
Eupraxia Pharmaceuticals
EPRX
$499M
$2.15M 0.46%
325,000
VTVT icon
12
vTv Therapeutics
VTVT
$132M
$1.88M 0.4%
+50,000
New +$1.73M
MRKR icon
13
Marker Therapeutics
MRKR
$20.3M
$478K 0.1%
325,370
OKUR
14
OnKure Therapeutics
OKUR
$143M
$404K 0.09%
88,607

Similar funds

Aisling Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Aisling Capital Management held 14 positions worth $472M, down 0.98% from $476M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Aisling Capital Management withdrew a net $33.3M in Q2 2026, reducing 1 holding. Its largest reduction was BridgeBio Pharma, cutting an estimated $35M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Aisling Capital Management opened a new position in vTv Therapeutics worth $1.88M.

  • Aisling Capital Management's largest Q2 2026 buy was vTv Therapeutics: 50,000 shares worth $1.88M.
  • Aisling Capital Management's biggest Q2 2026 reduction was BridgeBio Pharma, cutting an estimated $35M.
  • Aisling Capital Management's ten largest holdings make up 99% of its $472M portfolio in Q2 2026.
  • Aisling Capital Management opened 1 new position and closed 0 in Q2 2026.
  • Aisling Capital Management's portfolio value fell 0.98% quarter-over-quarter to $472M.

Based on Aisling Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.